Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fungemia Clear all
Completed Phase 3 Interventional

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Jun 10, 2026, 1:18 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

NCT01525095
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 10, 2026, 1:18 PM EDT
Completed No phase listed Observational

Serial Therapeutic and Antifungal Monitoring Protocol

NCT02163889
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jun 10, 2026, 1:18 PM EDT
Terminated Phase 1 Interventional

Micafungin Lock Therapy

NCT00809887
View directory record Official record
Conditions
Catheter-Related Fungal Infections
Interventions
Micafungin lock therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

NCT00001937
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
FK463, Fluconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

NCT01898208
View directory record Official record
Conditions
Bacteremia, Fungemia, Bloodstream Infection
Interventions
FilmArray testing, Antimicrobial Stewardship, Bacterial culture, Susceptibility testing
Device · Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Jun 10, 2026, 1:18 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

NCT00805740
View directory record Official record
Conditions
Candidiasis, Fungemia
Interventions
Active anidulafungin, Active Caspofungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Newark, Delaware • Wilmington, Delaware • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

NCT00672841
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Jun 10, 2026, 1:18 PM EDT
Completed No phase listed Observational

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

NCT00448942
View directory record Official record
Conditions
Nosocomial Bacteremia, Nosocomial Fungemia, MRSA Colonization, MRSA Infection, VRE Colonization, VRE Infection
Interventions
Daily bathing with Chlorhexidine based product
Behavioral
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Jun 10, 2026, 1:18 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

Voriconazole to Treat Fungal Infections

NCT00001940
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 1:18 PM EDT
Completed No phase listed Observational

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

NCT02719769
View directory record Official record
Conditions
Bacteremia, Fungemia
Interventions
Not listed
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
4,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

NCT00113191
View directory record Official record
Conditions
Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions
Veronate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Days to 5 Days
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia, Mycoses
Interventions
Isavuconazole, Caspofungin, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

NCT00839540
View directory record Official record
Conditions
Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jun 10, 2026, 1:18 PM EDT
Not yet recruiting No phase listed Observational

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

NCT06907992
View directory record Official record
Conditions
Candidemia
Interventions
Antifungal treatment
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

NCT02244606
View directory record Official record
Conditions
Mycoses, Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Micafungin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Jun 10, 2026, 1:18 PM EDT
Completed No phase listed Observational

Retrospective Chart Review of Candida Fungemia

NCT03827330
View directory record Official record
Conditions
Candida Fungemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jun 10, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288
View directory record Official record
Conditions
Candidiasis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jun 10, 2026, 1:18 PM EDT
Terminated Phase 3 Interventional

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 10, 2026, 1:18 PM EDT